Elicera – Presentation of Year-End report
Meet and ask questions to Elicera Therapeutics CEO, Jamal El-Mosleh in connection with the full year report for 2021. The CEO will dive into significant events during 2021 and give an update on latest events after the closure of the report.
Significant events in 2021: Elicera was listed on Nasdaq First North Growth Market on 11 June, Elicera Therapeutics submitted a patent application for development of ELC-201, the next generation of oncolytic viruses, Elicera Therapeutics received ATMP classification from the EMA for the oncolytic virus ELC-100 & Elicera Therapeutics enters agreement with BioNTech for contract manufacturing of viral vectors for CAR T-cell therapy.
Latest events 2022: Elicera Therapeutics strengthens IP protection for ELC-100 through acquisition of patent from Immunicum & Elicera Therapeutics secures 5 million SEK in funding from Vinnova to develop an automated CAR T-cell manufacturing process.
Elicera Therapeutics AB is a clinical phase cell and gene therapy company that develops the next generation of immuno-oncology treatments. The work is based on high-profile long-standing research conducted by Professor Magnus Essand's research group at Uppsala University and has resulted in the development of four drug candidates, including two CAR T cells and two oncolytic viruses. In addition, Elicera Therapeutics has developed a technology platform called iTANK that can be used to optimize all CAR T cells in development and activate killer T cells against cancer. The Elicera Therapeutics share (ELIC) is traded on Nasdaq First North Growth Market.
Disclaimer: HC Andersen Capital receives payment from Elicera for a Digital IR / Corporate Visibility subscription agreement.